Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AVANT Immunotherapeutics Inc. (Nasdaq: AVAN) -- Ignore unavailable to you. Want to Upgrade?

To: rrufff who wrote (478)	9/16/2003 8:35:03 PM
From: SemiBull	Read Replies (1) \| Respond to of 513

AVANT To Present At UBS Global Life Sciences Conference Tuesday September 16, 8:00 am ET NEEDHAM, Mass.--(BUSINESS WIRE)--Sept. 16, 2003--AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN - News) today announced that Dr. Una S. Ryan, President and Chief Executive Officer of AVANT Immunotherapeutics, Inc., will present at the UBS Global Life Sciences Conference at the Plaza Hotel in New York City on Tuesday, September 23rd at 12:00 noon, EDT. A live audio webcast of the presentation will be available online via the Investor Information area of AVANT's website at avantimmune.com. The audio replay of the presentation will begin 3 hours after the presentation time and will be available until October 25, 2003. The audio may also be accessed through the UBS conference site (www.ibb.ubs.com) as follows: click on the "Conferences" link in the middle of the page, then follow the link for "Webcast" under the Global Life Sciences Conference heading. Additionally, at the time of the presentation, Dr. Ryan's presentation slides will be posted as a read-only Adobe Acrobat (.pdf) file via the Investor Information area of AVANT's website, in the Presentations section. AVANT Immunotherapeutics, Inc. is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. The company is developing a broad portfolio of vaccines addressing a wide range of applications including bacterial and viral diseases, chronic human disease, biodefense and food safety. These include single-dose, oral vaccines that protect against important disease-causing agents and a novel, proprietary vaccine candidate for cholesterol management. AVANT's goal is to demonstrate proof-of-concept for its products before leveraging their value through partnerships. Current collaborations encompass the development of an oral human rotavirus vaccine, vaccines to combat threats of biological warfare, and vaccines addressed to human food safety and animal health. Additional information on AVANT Immunotherapeutics, Inc. can be obtained through our site on the World Wide Web: avantimmune.com. Contact: AVANT Immunotherapeutics, Inc. Una S. Ryan, Ph.D., 781-433-0771 or AVANT Immunotherapeutics, Inc. Avery W. Catlin, 781-433-0771 info@avantimmune.com or For Media: Kureczka/Martin Associates Joan Kureczka, 415-821-2413 jkureczka@aol.com Source: AVANT Immunotherapeutics, Inc.